First Tracks Biotherapeutics (TRAX) CEO Daniel Faga Receives Award

What Happened
Daniel Faga, President, CEO and a director of First Tracks Biotherapeutics (TRAX), was granted 193,575 performance-based restricted stock units (PSUs) on August 15, 2026. The Form 4 reports the award as a derivative acquisition at $0.00 per unit (total reported acquisition value $0). These PSUs are conditional rights to receive one share of common stock per PSU and are tied to performance criteria certified by the Compensation Committee.

Key Details

• Transaction date: August 15, 2026; Form 4 filed August 18, 2026 (appears timely).
• Transaction type/code: Award/Grant (A); 193,575 PSUs @ $0.00 (derivative).
• Footnotes: F1 — PSUs earned upon Certification of performance by the Compensation Committee on Aug 15, 2026. F2 — Each PSU equals one conditional share. F3 — Vesting/settlement schedule: 50% vest on Aug 15, 2027 and 50% vest on July 1, 2028, subject to continued service on each vesting date.
• Shares owned after the transaction: not disclosed in the provided filing.
• This is a compensation award (not an open-market purchase or sale); conversion to actual shares depends on meeting performance and service conditions.

Context
PSUs are a form of long-term incentive compensation: they only convert to shares if performance targets are met and the executive remains in service through vesting dates. Such awards signal board-approved compensation tied to performance, but they do not represent an immediate purchase or sale by the insider and will dilute shareholders only if and when the PSUs settle into shares.